Global Biologic Drugs Market to Jump to Over $220 Billion by 2019

Wednesday 20 November 2013, Amsterdam

ASDReports.com cites in its newly published “Expanding Markets for Biologics and Biosimilars” report that the global biologic drugs market will jump to over $220 billion by 2019.
    
Biologics, also known as biopharmaceuticals, can be categorized into three main modalities: therapeutic proteins, monoclonal antibodies and vaccines. Most of the biologic drugs marketed so far are recombinant therapeutic protein drugs, which are used to relieve patients suffering from chronic diseases, such as cancer, diabetes, cardiovascular diseases, infertility and cystic fibrosis. Globally, the U.S. commands 43% of biologics sales, followed by the E.U. (21%) and Japan (9%).

The “Expanding Markets for Biologics and Biosimilars” report covers key biologic and biosimilar drugs, including:

•    Humira (Adalimumab)
•    Remicade (Infliximab)
•    Lantus (Insulin Glargine)
•    Levemir (Insulin Detemir)
•    Privigen (Immune Globulin Intravenous)
•    Perjeta (Pertuzumab)
•    Soliris (Eculizumab)
•    Eylea (Aflibercept)
•    Revlimid (Lenalidomide)
•    Herceptin (Trastuzumab)
•    Gardasil
•    Varivax (Varicella Virus Vaccine Live)
•    Gammagard Liquid (Immune Globulin Infusion (Human))
•    Aranesp (Darbepoetin Alfa)
•    Enbrel (Etanercept)
•    Epogen/Procrit/Eprex/Erypo (Epoetin Alfa)
•    Genotropin (Somatropin)
•    Herceptin (Trastuzumab)
•    Humira (Adalimumab)
•    Neulasta (Pegfilgrastim)
•    Neupogen (Filgrastim)
•    Remicade (Infliximab)
•    Rituxan/MabThera (Rituximab)
    
The “Expanding Markets for Biologics and Biosimilars” report examines companies manufacturing biologic and biosimilar equipment and supplies in the world. Companies covered include: 3Bio, Abbott, AbbVie, Actelion, Amgen, Amoytop, Anhui Anke, Apotex, Astellas, AstraZeneca, Bayer, Beijing Four Rings, Bharat Serums and Vaccines, Biocon, Biogen Idec, Bioton, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene, Celltrion, Cipla, Dr. Reddy’s, Elan, Eli Lilly, Gideon Richter, Gilead Sciences, GlaxoSmithKline, Hospira, Intas, Johnson & Johnson, Merck, Mylan, Novartis, Pfizer, Roche, Sandoz, Sanofi, Stada Arzneimittel Aktiengesellschaft, Teva and Watson.